![Aaron](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/KF9Gdb7Wg7FCxJF44BPLu8uUyTQvPcdogzJ4mzQH.png)
Aaron Tan
National Cancer Centre Singapore
Singapore
![Aaron](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/KF9Gdb7Wg7FCxJF44BPLu8uUyTQvPcdogzJ4mzQH.png)
Aaron Tan
National Cancer Centre Singapore | Singapore
Dr Aaron is a Medical Oncologist at the National Cancer Centre Singapore (NCCS), having completed his specialty training in Medical Oncology (FRACP) in Sydney, Australia. He also completed a PhD in cancer drug discovery at The University of Sydney in 2011. At NCCS, he completed a fellowship in drug development/early phase trials and lung cancer translational research.
Sessions by this speaker
Thursday, 2024-08-29
BPOF Faculty
04:00 - 14:00
Thursday, 2024-08-29
Session 2: Precision Medicine and Lung Cancer
06:45 - 08:00
Lectures by this speaker
Thursday, 2024-08-29
Integrating Agnostic Markers Across Solid Tumors: Defining the Art of Precision Oncology
05:45 - 06:00
Thursday, 2024-08-29
Molecular Tumor Board 1: Agnostic Markers in Precision Oncology: Challenging Cases
06:00 - 06:30
Thursday, 2024-08-29
Molecular Tumor Board 2: Precision Oncology and Lung Cancer- Challenging Cases
07:35 - 08:00
![Alvin](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/QpxKwHtrGrsSwtqSSoLW8o8NxuMf80i8BhFtIgRk.png)
Alvin Wong
National University Cancer Institute
Singapore
![Alvin](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/QpxKwHtrGrsSwtqSSoLW8o8NxuMf80i8BhFtIgRk.png)
Alvin Wong
National University Cancer Institute | Singapore
Dr Alvin Wong graduated from NUS in 1992 and completed his training in medical oncology with the Department of Haematology Oncology in 2001 where he now serves as senior consultant. He did a laboratory stint in Tumour Immunology at Johns Hopkins University, Baltimore in 2002. He sub-specialises in genitourinary malignancies (kidney, prostate, bladder and germ cell cancers). His research collaborations include the investigation of Tumour Associated Macrophages in Renal Cell Carcinoma (Singapore Immunology Network) and the epidemiology of prostate cancer (NUS Epidemiology & Public Health). He has published on a range of topics in local and international journals and enjoys a ‘seamless’ approach to GU cancers with his trainees and colleagues. He maintains a lively interest in bioethical issues.
Sessions by this speaker
Thursday, 2024-08-29
BPOF Faculty
04:00 - 14:00
Lectures by this speaker
Thursday, 2024-08-29
Molecular Tumor Board 4: Precision Oncology for Prostate Cancer: Challenging Cases
10:05 - 10:30
![Amanda](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/ST8ZpfyhZHMABndSHwVvruvrHEUtRXiwGNcSxXvh.png)
Amanda Seet
National Cancer Centre Singapore
Singapore
![Amanda](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/ST8ZpfyhZHMABndSHwVvruvrHEUtRXiwGNcSxXvh.png)
Amanda Seet
National Cancer Centre Singapore | Singapore
Dr Seet is currently working in the National Cancer Centre, Singapore as an Associate Consultant (thoraicic, head and neck, genitourinary oncology). She also has prior experience in phase I clinical trial recruitment.
Sessions by this speaker
Thursday, 2024-08-29
BPOF Faculty
04:00 - 14:00
Lectures by this speaker
Thursday, 2024-08-29
Understanding the Power of Liquid Biopsy in Precision Oncology
05:30 - 05:45
Thursday, 2024-08-29
Molecular Tumor Board 1: Agnostic Markers in Precision Oncology: Challenging Cases
06:00 - 06:30
![Andrea](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/CUzXprSiupnmKQwd9tKotfrrD9hHVz4rV5EjM4pr.png)
Andrea Wong
National University Cancer Institute
Singapore
![Andrea](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/CUzXprSiupnmKQwd9tKotfrrD9hHVz4rV5EjM4pr.png)
Andrea Wong
National University Cancer Institute | Singapore
Dr Andrea Wong completed her undergraduate medical degree at the University of Glasgow, and obtained her postgraduate qualifications from the Royal College of Physicians, United Kingdom as well as the National University of Singapore. She specializes in breast and brain cancers and actively contributes to cancer research through her role as an investigator in several clinical trials conducted at the National University Cancer Institute, Singapore (NCIS). She is currently performing translational research work related to the development of novel targeted therapies for the treatment of advanced cancer in her capacity as an Adjunct Research Fellow at the Cancer Science Institute, Singapore. She has received multiple research grants for her work, including the Singapore National Medical Research Council Transition Award in 2018. In addition, she has authored several publications in peer-reviewed oncology and pharmacogenetics journals, and is a member of the Singapore Society of Oncology.
Sessions by this speaker
Thursday, 2024-08-29
BPOF Faculty
04:00 - 14:00
Lectures by this speaker
Thursday, 2024-08-29
HER2 Low and HER2 Positive: Challenging Cases
10:45 - 11:15
![Aneez](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/uFdJvZ0cjexYXV2bvmmIeLJ1k3WPfUVgaCEcQw7V.png)
Aneez Ahmed
Mount Elizabeth Novena Hospital
Singapore
![Aneez](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/uFdJvZ0cjexYXV2bvmmIeLJ1k3WPfUVgaCEcQw7V.png)
Aneez Ahmed
Mount Elizabeth Novena Hospital | Singapore
Dr Aneez D.B Ahmed is currently the Director & Senior Consultant Surgeon at International Centre for Thoracic Surgery in Mount Elizabeth Novena Specialist Centre, Singapore. He has been a practitioner in the field of thoracic surgery, with a special interest in thoracic oncology, for more than fifteen years. After completion of his cardiothoracic training from National University Hospital, Singapore, he passed his Fellowship exams from the Royal College of Surgeons of Edinburgh. Prior to starting his private practice, Dr Aneez served as the Head of Service of Thoracic Surgery in the Department of General Surgery in Tan Tock Seng Hospital (TTSH), Singapore. His interest in robotic surgery led him to be recognised as the first in the ASEAN cohort to get a Level III Certificate Specialist training in Robotic Thoracic Surgery from the European College of Cardiothoracic Surgery (EACTS). With sabbaticals in Europe and USA for advanced training in Robotic Thoracic surgery, he now leads the training program for thoracic surgeons in ASEAN and South Asia. He then became the Vice President of Robotic Surgical Society of Singapore (RS3) in 2016 and subsequently being nominated as the President of RS3 in 2019. His special interest in chest wall surgery led him to be a pioneer in Chest Wall Resection and Reconstruction. Dr Aneez had also performed the world’s first 3D Printed Polymer Ribcage Reconstruction. Dr Aneez is a member of various thoracic surgical groups internationally. He is also the Thoracic domain board member at the Asian Society of Cardiothoracic Surgery (ASCVTS), and he is the current General Secretary of the South East Asian Society of Thoracic Surgery (SEATS). His expertise and knowledge in minimally invasive thoracic surgery have led to numerous invitations as a speaker to conferences and workshops in the region. He also receives referrals from other hospitals in the country and other regions such as Malaysia, Thailand, Philippines and the U.A.E. Besides clinical works, Dr Aneez is passionate about teaching. Since 2010, Dr Aneez piloted a program in Advanced Thoracic Nursing Course (ATNC) at TTSH that has been running annually to train nurses from all over Asia. He is also an examiner for the Royal College of Surgeons of Edinburgh.
Sessions by this speaker
Thursday, 2024-08-29
BPOF Faculty
04:00 - 14:00
Lectures by this speaker
Thursday, 2024-08-29
Molecular Tumor Board 2: Precision Oncology and Lung Cancer- Challenging Cases
07:35 - 08:00
![Benita](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/Ld7BDyb3h19i91YUc9M0uBDHOryoOjAk8KrCbfg2.png)
Benita Tan
Sengkang General Hospital
Singapore
![Benita](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/Ld7BDyb3h19i91YUc9M0uBDHOryoOjAk8KrCbfg2.png)
Benita Tan
Sengkang General Hospital | Singapore
Clinical Professor Benita Tan is a Senior Consultant in the Department of General Surgery in Sengkang General Hospital, and the current Chairman of the Division of Surgery at Sengkang General Hospital. She is also a Senior Consultant at the Department of Breast Surgery, Singapore General Hospital and Division of Surgical Oncology in National Cancer Centre, Singapore.
Sessions by this speaker
Thursday, 2024-08-29
BPOF Faculty
04:00 - 14:00
Lectures by this speaker
Thursday, 2024-08-29
Molecular Tumor Board 5: Integrating IO and ADCs in Triple Negative Breast Cancer
11:30 - 12:00
![Beung](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/W6dsjZSEXuFQmVcHzorR4XlgkSLIzXOlPaP7RNUb.png)
Beung Chul-Ahn
National Cancer Center
Korea South
![Beung](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/W6dsjZSEXuFQmVcHzorR4XlgkSLIzXOlPaP7RNUb.png)
Beung Chul-Ahn
National Cancer Center | Korea South
Dr. Beung-Chul-Ahn is an Assistant Professor at the Center for Lung Cancer, Hospital Division of Hemato-Oncology, Department of Internal Medicine Research Institute and Hospital, National Cancer Center, Republic of Korea.
Sessions by this speaker
Thursday, 2024-08-29
BPOF Faculty
04:00 - 14:00
Lectures by this speaker
Thursday, 2024-08-29
Optimizing Advanced NSCLC Management with Liquid Biopsy – Satellite Symposium by Guardant
07:15 - 07:35
Thursday, 2024-08-29
Molecular Tumor Board 2: Precision Oncology and Lung Cancer- Challenging Cases
07:35 - 08:00
![Chiang](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/PXUWzfDX2DgruavVDjoyual8Le7hG57SqVUJsFGR.png)
Chiang Jianbang
National Cancer Centre Singapore
Singapore
![Chiang](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/PXUWzfDX2DgruavVDjoyual8Le7hG57SqVUJsFGR.png)
Chiang Jianbang
National Cancer Centre Singapore | Singapore
Dr Chiang Jianbang is a Consultant in Medical Oncology at the National Cancer Centre Singapore (NCCS). He focuses on cancer genetics in NCCS and works with a team of dedicated geneticists and genetic counsellors. He hopes to empower patients, family members and healthcare professionals with cancer genetics knowledge to improve personal and public health. His interests are in clinical cancer genetics, genomic medicine and implementation science.
Sessions by this speaker
Thursday, 2024-08-29
BPOF Faculty
04:00 - 14:00
Lectures by this speaker
Thursday, 2024-08-29
Integrating Germline Testing into Precision Medicine
05:15 - 05:30
Thursday, 2024-08-29
Molecular Tumor Board 1: Agnostic Markers in Precision Oncology: Challenging Cases
06:00 - 06:30
![David](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/AZZYSOWZRe1DdXQ2zU4sFFai88LAAvOpwDUUg8xX.png)
David Tan
National University Cancer Institute
Singapore
![David](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/AZZYSOWZRe1DdXQ2zU4sFFai88LAAvOpwDUUg8xX.png)
David Tan
National University Cancer Institute | Singapore
Dr David Tan is a medical oncologist and clinician scientist at the National University Cancer Institute, Singapore. He is an Associate Professor at the Yong Loo Lin School of Medicine, NUS and Principal Investigator at the Cancer Science Institute, NUS. He is also Head of the Innovation Transfer Office at National University Health Systems (NUHS). His primary clinical and research interests are in gynaecological (ovarian, endometrial and cervical) cancers and the development of novel anti-cancer therapeutic agents.
Sessions by this speaker
Thursday, 2024-08-29
BPOF Faculty
04:00 - 14:00
Thursday, 2024-08-29
Session 3: Precision Medicine in GU And Gynae Malignancies
08:00 - 10:30
Lectures by this speaker
Thursday, 2024-08-29
Molecular Tumor Board 3: Precision Oncology for Gynae Malignancies: Immunotherapy, Parpi and Beyond!
08:15 - 08:45
![Ee](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/ChYRRY0Fk43rAy3l6pGgcahK7ojjZ6wQo3G9SBei.png)
Ee Tat Xin
KK Women's and Children's Hospital
Singapore
![Ee](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/ChYRRY0Fk43rAy3l6pGgcahK7ojjZ6wQo3G9SBei.png)
Ee Tat Xin
KK Women's and Children's Hospital | Singapore
Dr Ee Tat Xin is a Consultant at KK Women's and Children's Hospital, Singapore. His specialty is Obstetrics & Gynaecology, Reproductive Medicine and Sub-specialty is Reproductive Medicine. His areas of research interest are female infertility, male infertility, endometriosis, fertility in oncological patients.
Sessions by this speaker
Thursday, 2024-08-29
BPOF Faculty
04:00 - 14:00
Lectures by this speaker
Thursday, 2024-08-29
Molecular Tumor Board 3: Precision Oncology for Gynae Malignancies: Immunotherapy, Parpi and Beyond!
08:15 - 08:45
![Esther](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/xSxCvL7EZIrn8oSKCyWQNcmpaj88vsH3ONBeKtbw.png)
Esther Chang
National Cancer Centre Singapore
Singapore
![Esther](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/xSxCvL7EZIrn8oSKCyWQNcmpaj88vsH3ONBeKtbw.png)
Esther Chang
National Cancer Centre Singapore | Singapore
Dr Chang Wei Yin Esther is Consultant in the Division of Medical Oncology at National Cancer Centre, Singapore. She obtained her MD from Duke-NUS Medical School in 2012. Prior to that she did her undergraduate studies in biomedical science in NUS and obtained first class honours in 2008. Dr Chang currently subspecializes in the treatment of lymphoma, sarcoma and melanoma. Her interest in cancer biology and immunology started as a medical student when she worked on a research project on myeloid derived suppressor cells in gastric cancer patients.
Sessions by this speaker
Thursday, 2024-08-29
BPOF Faculty
04:00 - 14:00
Lectures by this speaker
Thursday, 2024-08-29
Molecular Tumor Board 1: Agnostic Markers in Precision Oncology: Challenging Cases
06:00 - 06:30
![Faye](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/KabTJZBLoidyusd8zBZKgMB3LQvevMsoFvaNR8W6.png)
Faye Lim
National Cancer Center Singapore
Singapore
![Faye](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/KabTJZBLoidyusd8zBZKgMB3LQvevMsoFvaNR8W6.png)
Faye Lim
National Cancer Center Singapore | Singapore
Dr Faye Lim is a Senior Radiation Oncologist at the National Cancer Centre Singapore who specializes in both Breast and Gastrointestinal Cancers. She trained at the Mount Vernon Cancer Centre and the University College London Hospitals in the United Kingdom. She has a special interest in the use and optimization of proton therapy in breast and GI cancers and is the Clinical Lead for proton therapy in the treatment of breast cancer.
Sessions by this speaker
Thursday, 2024-08-29
APGCS Faculty
04:00 - 14:00
Thursday, 2024-08-29
BPOF Faculty
04:00 - 14:00
Lectures by this speaker
Saturday, 2024-08-31
Round Table Panel Discussion on MDT Case
06:00 - 06:30
Thursday, 2024-08-29
HER2 Low and HER2 Positive: Challenging Cases
10:45 - 11:15
![Felicia](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/tXRxXl7ee6gsqKewGVQMxNEGZxRwJnfQPhR293f5.png)
Felicia Chin
KK Women's and Children's Hospital
Singapore
![Felicia](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/tXRxXl7ee6gsqKewGVQMxNEGZxRwJnfQPhR293f5.png)
Felicia Chin
KK Women's and Children's Hospital | Singapore
Dr Felicia Chin is a Senior Consultant with the Department of Gynaecological Oncology, KK Women's and Children's Hospital, Singapore. She graduated from the Yong Loo Lin School of Medicine, National University of Singapore, in 2008, attatined specialist accreditation in Obstetrics and Gynaecology in 2016, and underwent subspecialty training in Gynaecological Oncology. She was awarded the Singhealth Health Manpower Development Plan Award in 2019 and completed her fellowship in Fertility Sparing Management in Gynaecological Cancers at the Royal Women’s Hospital, Melbourne. In 2020, Dr Chin spearheaded the Gynae Oncofertility Service in KKH, a first-in-Singapore service, which provides multidisciplinary, holistic care for young women with cancer, with a focus on fertility preservation.
Sessions by this speaker
Thursday, 2024-08-29
BPOF Faculty
04:00 - 14:00
Lectures by this speaker
Thursday, 2024-08-29
Molecular Tumor Board 3: Precision Oncology for Gynae Malignancies: Immunotherapy, Parpi and Beyond!
08:15 - 08:45
![Herbert](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/2HhgNm0l6lA8hNacujdJPoV2YmABYHzTGvb2qtvT.png)
Herbert Loong
The Chinese University of Hong Kong
Hong Kong
![Herbert](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/2HhgNm0l6lA8hNacujdJPoV2YmABYHzTGvb2qtvT.png)
Herbert Loong
The Chinese University of Hong Kong | Hong Kong
Dr. Herbert Ho-fung Loong holds conjoint appointments of Clinical Associate Professor in the Department of Clinical Oncology and Deputy Medical Director of the Phase 1 Clinical Trials Centre of The Chinese University of Hong Kong. Dr. Loong obtained his medical degree with a Distinction in Surgery from The University of Hong Kong in 2003. He has completed a Fellowship in Drug Development at Princess Margaret Cancer Centre in Toronto, Canada with a focus on Experimental Therapeutics. His clinical and research interests include Thoracic Oncology, Sarcoma Medical Oncology and Health Economics. Dr. Loong led the Lung Cancer Team at CUHK to be bestowed the IASLC Foundation Cancer Care Team Award in recognition for providing the best thoracic oncology care in “Asia & Rest of the World” in 2018. In recent years, Dr. Loong has co-founded the Asia Pacific Oncology Drug Development Consortium (APODDC) and the Asia Pacific Coalition Against Lung Cancer (APCLC). Dr. Loong has served or continues to serve in various capacities in various professional international oncology bodies, including the International Affairs Committee and the Asia-Pacific Regional Council of ASCO, the Membership, Education and Communications Committees of the IASLC. He is the current Chair of the International Affairs Committee of ASCO in 2024. He has been elected as a Board Member of the Connective Tissue Oncology Society (CTOS) for 2022-2024. In his prior appointment as a member of Pharmacy and Poisons Board of Hong Kong, he oversaw the registration of medicinal products and clinical trials in the territory.
Sessions by this speaker
Thursday, 2024-08-29
BPOF Faculty
04:00 - 14:00
Lectures by this speaker
Thursday, 2024-08-29
Selpercatinib in Precision Oncology: Optimizing Treatment Strategies for RET Fusion-Positive NSCLC and Beyond – Satellite Symposium by DKSH
06:45 - 07:15
Thursday, 2024-08-29
Molecular Tumor Board 2: Precision Oncology and Lung Cancer- Challenging Cases
07:35 - 08:00
![Johan](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/0X4sYohbRkxcjii6BpjUJ1eUVcU6cfZzWbp0tXxS.png)
Johan Chan
National Cancer Centre Singapore
Singapore
![Johan](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/0X4sYohbRkxcjii6BpjUJ1eUVcU6cfZzWbp0tXxS.png)
Johan Chan
National Cancer Centre Singapore | Singapore
Dr Johan Chan is a Consultant in the Division of Medical Oncology of the National Cancer Centre Singapore. He completed his medical oncology specialty training in Australia. As part of his specialist training, he completed a fellowship in National Cancer Centre Singapore and continued practising as an Associate Consultant. His research interest includes GU oncology and Geriatric oncology.
Sessions by this speaker
Thursday, 2024-08-29
BPOF Faculty
04:00 - 14:00
Lectures by this speaker
Thursday, 2024-08-29
Integrating Targeted Therapy/ Luteitum Therapy in Prostate Cancer
09:45 - 10:05
Thursday, 2024-08-29
Molecular Tumor Board 4: Precision Oncology for Prostate Cancer: Challenging Cases
10:05 - 10:30
![Joline](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/sICUJc1EGdXhgrf71e3hI132huuMPyiFbLd9UFfn.png)
Joline Lim
National University Cancer Institute
Singapore
![Joline](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/sICUJc1EGdXhgrf71e3hI132huuMPyiFbLd9UFfn.png)
Joline Lim
National University Cancer Institute | Singapore
Dr Joline Lim is a Senior Consultant and Clinician Scientist at the National University Cancer Institute, Singapore. Her primary clinical and research interests are in breast oncology and early phase clinical trials, with a special focus on the development of novel anti-cancer therapeutic agents and biomarkers.
Sessions by this speaker
Thursday, 2024-08-29
BPOF Faculty
04:00 - 14:00
Thursday, 2024-08-29
Session 4: Precision Medicine in Breast Cancer
10:30 - 12:05
Lectures by this speaker
Thursday, 2024-08-29
Molecular Tumor Board 5: Integrating IO and ADCs in Triple Negative Breast Cancer
11:30 - 12:00
![Joshua](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/xiyOPBgsiBvN3km18VvHU4Ud7aA23lpUwX8bjO1h.png)
Joshua Tan
National Cancer Centre Singapore
Singapore
![Joshua](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/xiyOPBgsiBvN3km18VvHU4Ud7aA23lpUwX8bjO1h.png)
Joshua Tan
National Cancer Centre Singapore | Singapore
Dr Joshua Tan is an associate consultant in the department of medical oncology at National Cancer Centre Singapore specializing in breast and gynaecological cancers
Sessions by this speaker
Thursday, 2024-08-29
BPOF Faculty
04:00 - 14:00
Lectures by this speaker
Thursday, 2024-08-29
Immunotherapy and Parpi in Gyne Malignancies: Is it for Everyone or a Select Few?
08:00 - 08:15
Thursday, 2024-08-29
Molecular Tumor Board 3: Precision Oncology for Gynae Malignancies: Immunotherapy, Parpi and Beyond!
08:15 - 08:45
![Karmen](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/WYgrgNVQNN9ilEsLU2m3p93KUguFgWsHrupvoKIV.png)
Karmen Wong
Icon Cancer Center
Singapore
![Karmen](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/WYgrgNVQNN9ilEsLU2m3p93KUguFgWsHrupvoKIV.png)
Karmen Wong
Icon Cancer Center | Singapore
Dr Karmen Wong is a medical oncologist with more than 30 years of clinical practice. She received her oncology training at the National University Hospital (NUH), National Cancer Centre, Singapore (NCC) and University of California, San Francisco (UCSF), who have a reputation for health sciences research and patient care under the HMDP scholarship. She helped establish the first multi-disciplinary breast cancer treatment in Singapore 20 years ago in NCC, which created a platform for treatment in other cancer types with doctors of different disciplines. Dr Wong also initiated the bone marrow transplant programme in solid tumour in Singapore General Hospital (SGH) in 1997. She also won an award for her oral presentation at the 9th Annual Scientific Meeting in SGH in 1988. She is also currently running a strong cancer support network in her practice. In addition, she is also a co-investigator in various clinical trials on new cancer treatments. These include the CompLEEment-1 trial study that were presented in ASCO 2019 (American Society of Medical Oncology) and ESMO 2018 (European Society for Medical Oncology) meetings.
Sessions by this speaker
Thursday, 2024-08-29
BPOF Faculty
04:00 - 14:00
Lectures by this speaker
Thursday, 2024-08-29
Molecular Tumor Board 5: Integrating IO and ADCs in Triple Negative Breast Cancer
11:30 - 12:00
![Kenneth](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/vR4iQzyL8lqNmBM7cfcW5uwXol5pUiWgv53nvUJE.png)
Kenneth Chen
Singapore General Hospital
Singapore
![Kenneth](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/vR4iQzyL8lqNmBM7cfcW5uwXol5pUiWgv53nvUJE.png)
Kenneth Chen
Singapore General Hospital | Singapore
Dr. Kenneth Chen is a senior consultant uro-oncologist at Singapore General Hospital. Dr. Chen specialises in robotic and minimally invasive surgery for genitourinary oncology, having completed an oncology fellowship at the Sir Peter MacCallum Cancer Centre in Melbourne, Australia. His academic and research interests include prostate cancer diagnostics, advanced prostate cancer management, and novel device development. He has been awarded a National Medical Research Council (NMRC) grant for work on a drug-eluting stent to treat ureteric diseases.
Sessions by this speaker
Thursday, 2024-08-29
BPOF Faculty
04:00 - 14:00
Lectures by this speaker
Thursday, 2024-08-29
Molecular Tumor Board 4: Precision Oncology for Prostate Cancer: Challenging Cases
10:05 - 10:30
![Lee](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/v5i5YNMLRkQ6BCGiwjTBrd2rYVtNk1zKPBfpiCww.png)
Lee Han Yi
National Cancer Centre Singapore
Singapore
![Lee](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/v5i5YNMLRkQ6BCGiwjTBrd2rYVtNk1zKPBfpiCww.png)
Lee Han Yi
National Cancer Centre Singapore | Singapore
Dr Lee Han Yi, MMB (S’pore), MRCP (UK), MMed (S’pore) is a Medical Oncologist at the National Cancer Centre Singapore. She obtained her MBBS from the NUS Yong Loo Lin School of Medicine. She obtained her MRCP, MMed (NUS) in 2019 and graduated from the Medical Oncology Specialist Programme. Dr Lee’s sub-specialty interests are breast and CNS cancer. She currently practices at NCCS, KKH, SKH and NNI.
Sessions by this speaker
Thursday, 2024-08-29
BPOF Faculty
04:00 - 14:00
Lectures by this speaker
Thursday, 2024-08-29
The Spectrum of HER2 in Breast Cancer: From Low Expression to Pathogenic Mutations
10:30 - 10:45
![Lee](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/lGMM9JmboyBgBNO4wUgVZkPrZtG0Rp1Cz5ztb6mv.png)
Lee Soo Chin
National University Cancer Institute
Singapore
![Lee](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/lGMM9JmboyBgBNO4wUgVZkPrZtG0Rp1Cz5ztb6mv.png)
Lee Soo Chin
National University Cancer Institute | Singapore
Prof. Lee Soo Chin specialises in breast cancer and directs the Cancer Genetics program at NCIS. Her research focus is on breast cancer, pharmacogenetics and cancer genetics, and she has been the Principal Investigator of more than 40 industry-sponsored and investigator-initiated breast cancer clinical trials. She directs the Haematology-Oncology Research Group, a cancer clinical trials unit that conducts 200 phase I-III therapeutics clinical trials in solid tumours and haematological malignancies at the National University Cancer Institute.
Sessions by this speaker
Thursday, 2024-08-29
BPOF Faculty
04:00 - 14:00
Thursday, 2024-08-29
Session 4: Precision Medicine in Breast Cancer
10:30 - 12:05
Lectures by this speaker
Thursday, 2024-08-29
HER2 Low and HER2 Positive: Challenging Cases
10:45 - 11:15
Thursday, 2024-08-29
Biomarker Driven Approach to Managing HR+Ve Breast Cancer
11:15 - 11:30
Thursday, 2024-08-29
Molecular Tumor Board 5: Integrating IO and ADCs in Triple Negative Breast Cancer
11:30 - 12:00
![Ma](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/xGGRwXR6j1EhX24nCIeDq7cOpUG2aRnB6PKzEIRh.png)
Ma Jun
National Cancer Centre Singapore
Singapore
![Ma](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/xGGRwXR6j1EhX24nCIeDq7cOpUG2aRnB6PKzEIRh.png)
Ma Jun
National Cancer Centre Singapore | Singapore
Dr Ma Jun received her undergraduate degree from Monash University, Australia. She trained in Medical Oncology in National Cancer Centre Singapore and is currently specialising in breast cancer treatment. She has a special interest in young women with breast cancer as well as supportive care needs in breast cancer.
Sessions by this speaker
Thursday, 2024-08-29
BPOF Faculty
04:00 - 14:00
Lectures by this speaker
Thursday, 2024-08-29
HER2 Low and HER2 Positive: Challenging Cases
10:45 - 11:15
![Muhammad](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/MyB3hlQyoh0EPprAb4eFXpF528QfehRi7MJtbTXe.png)
Muhammad Azrif
Prince Court Medical Centre
Malaysia
![Muhammad](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/MyB3hlQyoh0EPprAb4eFXpF528QfehRi7MJtbTXe.png)
Muhammad Azrif
Prince Court Medical Centre | Malaysia
Dr. Muhammad Azrif graduated from the Royal Free Hospital & University College London School of Medicine, London, UK in 1997. After completing his training in internal medicine and obtaining his MRCP (UK) in 2000, he entered the specialist training program in Clinical Oncology at the Christie Hospital, Manchester, UK. He became a Fellow of the Royal College of Radiologists (Clinical Oncology) in 2005 and attained his Certificate of Completion of Specialist Training (UK) before admission to the UK General Medical Council Specialist Register in 2006. He was awarded a one-year Clinical Research Fellowship to the Department of Radiation Oncology, University of Toronto, Canada in mid-2006. He returned to Malaysia in 2007 and served at the National University of Malaysia Medical Centre (UKMMC) as a Consultant Clinical Oncologist for 5 years before joining private practice in 2012. He has served on various national oncology committees, published in peer-reviewed journals as well as participated in numerous clinical trials, cancer advisory boards, and expert panels.
Sessions by this speaker
Thursday, 2024-08-29
BPOF Faculty
04:00 - 14:00
Thursday, 2024-08-29
APGCS Faculty
04:00 - 14:00
Lectures by this speaker
Thursday, 2024-08-29
Molecular Tumor Board 1: Agnostic Markers in Precision Oncology: Challenging Cases
06:00 - 06:30
Thursday, 2024-08-29
Molecular Tumor Board 2: Precision Oncology and Lung Cancer- Challenging Cases
07:35 - 08:00
Friday, 2024-08-30
Multidisciplinary Management of Advanced Gastroesophageal Cancers
08:20 - 08:40
Friday, 2024-08-30
Pancreatic MDT
11:55 - 12:25
![Samuel](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/eRSkMBkC3ASi73dg1vPrDdcJmfl1gTXcwfOYXTt1.png)
Samuel Ow
National University Cancer Institute
Singapore
![Samuel](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/eRSkMBkC3ASi73dg1vPrDdcJmfl1gTXcwfOYXTt1.png)
Samuel Ow
National University Cancer Institute | Singapore
Dr Samuel Ow is a Senior Consultant Medical Oncologist in the Department of Haematology-Oncology, National University Cancer Institute, Singapore (NCIS). Dr Samuel Ow's clinical and research interests are in Breast Cancer and Clinical Cancer Genetics. He is a co-investigator in several investigator-initiated and multi-national clinical trials, and has published his research in peer-reviewed journals. He is an alumnus of the Clinical Cancer Genetics Community of Practice Intensive Course in Cancer Risk Assessment conducted by the City of Hope Comprehensive Cancer Center, and currently runs the Cancer Genetics Clinic at NCIS.
Sessions by this speaker
Thursday, 2024-08-29
BPOF Faculty
04:00 - 14:00
Lectures by this speaker
Thursday, 2024-08-29
HER2 Low and HER2 Positive: Challenging Cases
10:45 - 11:15
![See](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/mFRT1IbUwWCYYBSKiE2hwA7XaLeaELX2wQYLknSu.png)
See Hui Ti
Parkway Cancer Centre
Singapore
![See](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/mFRT1IbUwWCYYBSKiE2hwA7XaLeaELX2wQYLknSu.png)
See Hui Ti
Parkway Cancer Centre | Singapore
Dr See Hui Ti is a Senior Consultant, Medical Oncologist at Parkway Cancer Centre. Dr See Hui Ti was awarded the Singapore Government HMDP fellowship in 2002 after completing advanced oncology training at the National Cancer Centre. From 2003 to 2004, she furthered her training in Medical Oncology at the M.D. Anderson Cancer Center in Houston, Texas. Dr See Hui Ti was previously a Consultant in Medical Oncology at the National Cancer Centre as well as a visiting Consultant at the KK Women’s and Children’s Hospital specializing in adult breast and gynecologic cancers. She is registered with the General Medical Council (UK), and worked at Queen Elizabeth Hospital in Birmingham, UK, before continuing her internal medicine training at the Singapore General Hospital. Dr See Hui Ti is a member of the International Gynecologic Cancer Society, American Society of Clinic Oncology and the Singapore Medical Association. She served as an executive committee member of the Singapore Society of Oncology from 2001 to 2007.
Sessions by this speaker
Thursday, 2024-08-29
BPOF Faculty
04:00 - 14:00
Lectures by this speaker
Thursday, 2024-08-29
Molecular Tumor Board 3: Precision Oncology for Gynae Malignancies: Immunotherapy, Parpi and Beyond!
08:15 - 08:45
![Shaheenah](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/ZzGaAZERU3t1EZl7qdkpH0c6VJL972zgcvLhJB03.png)
Shaheenah Dawood
Mediclinic City Hospital
United Arab Emirates
![Shaheenah](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/ZzGaAZERU3t1EZl7qdkpH0c6VJL972zgcvLhJB03.png)
Shaheenah Dawood
Mediclinic City Hospital | United Arab Emirates
Dr Shaheenah Dawood is a Consultant Medical Oncologist and Professor in Clinical Oncology in the United Arab Emirates. She was trained in medical oncology at McGill University Hospitals in Canada and subspecialized in breast cancer management at MD Anderson Cancer Center. During her training, she was awarded multiple scholar training awards besides ASCO merit awards. Dr Shaheenah has served as an editorial fellow at the New England Journal of Medicine and has an MPH from the Harvard School of Public Health. She has over 100 papers to her credit including 50 peer review original articles, 30 review articles, and 12 book chapters. Having served as a reviewer for multiple journals including the Journal of Clinical Oncology she is currently leading the oncology clinical trials program at Mediclinic City Hospital, Dubai. She also serves as President of Excellence in Oncology Care (EIOC) annual congress held in Dubai and is Co-Chair of the Asia Pacific Breast Cancer Summit (APBCS), Asia Pacific Gastrointestinal Cancer Summit (APGCS) ,the international BRCA forum (iBRCAf) and Young Women Forum (YWF) from over a decade.
Sessions by this speaker
Thursday, 2024-08-29
BPOF Faculty
04:00 - 14:00
Thursday, 2024-08-29
APGCS Faculty
04:00 - 14:00
Friday, 2024-08-30
Session 1: Keynotes & Updates: UGI
04:45 - 07:00
Lectures by this speaker
Thursday, 2024-08-29
Welcome Remarks
04:45 - 05:00
Friday, 2024-08-30
Wrapping Up the Year: Updates in GI Malignancies
05:00 - 05:25
Friday, 2024-08-30
In Conversation with the Experts: Critical Updates in Upper GI Malignancies
06:15 - 06:45
Thursday, 2024-08-29
Molecular Tumor Board 1: Agnostic Markers in Precision Oncology: Challenging Cases
06:00 - 06:30
![Steven](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/KZP3dqxgKs4oqzzYVVNXwgITOnPZqQnPoiQmxEwX.png)
Steven Tucker
Tucker Medical
Singapore
![Steven](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/KZP3dqxgKs4oqzzYVVNXwgITOnPZqQnPoiQmxEwX.png)
Steven Tucker
Tucker Medical | Singapore
Dr. Steven Tucker is a senior consultant medical oncologist and founder of Tucker Medical, a Singapore-based multidisciplinary medical practice. His subspecialty interest is in personalised screening, prevention, and treatment of breast and prostate cancers. He is a Fellow of the Singapore Academy of Medicine and the American College of Physicians. Dr. Tucker is also the Medical Director for Cedars-Sinai International in Singapore, overseeing regional care and clinical partnerships. Dr. Tucker trained in Internal Medicine, Hematology, Oncology, and Stem Cell Transplantation at the UCLA Center for Health Sciences. While at UCLA, he studied molecular biology and joined the UCLA faculty as an Assistant Professor of Clinical Medicine in 1999. He was previously a member of the Breast Cancer Faculty at the John Wayne Cancer Institute, the Prostate & Genitourinary Oncology Program Director at The Angeles Clinic & Research Institute, and a Guest Investigator at Rockefeller University. In addition to patient care, Dr. Tucker is a professional speaker, foresight strategist, and consultant. He advises on novel health and medical technology with start-ups, venture funds, multinationals, and governments
Sessions by this speaker
Thursday, 2024-08-29
BPOF Faculty
04:00 - 14:00
Lectures by this speaker
Thursday, 2024-08-29
HER2 Low and HER2 Positive: Challenging Cases
10:45 - 11:15
![Tanujaa](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/klFv4J9vcGYnrIswUi5iReFozwh1YwPGrbtk6kni.png)
Tanujaa Rajasekaran
Parkway Cancer Centre
Singapore
![Tanujaa](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/klFv4J9vcGYnrIswUi5iReFozwh1YwPGrbtk6kni.png)
Tanujaa Rajasekaran
Parkway Cancer Centre | Singapore
Dr Tanujaa Rajasekaran is a Senior Consultant, Medical Oncologist at Parkway Cancer Centre. She is experienced in general medical oncology, with subspecialty interests in the management of lung, genitourinary, head and neck cancers and geriatric oncology. Prior to joining Parkway Cancer Centre, Dr Tanujaa served as a Consultant at National Cancer Centre Singapore and as the Medical Director of the Changi General Hospital oncology unit. Dr Tanujaa is actively involved in medical education. She was a core faculty member of the Medical Oncology Senior Residency Program, as well as a Clinical lecturer at Yong Loo Lin School of Medicine, NUS.
Sessions by this speaker
Thursday, 2024-08-29
BPOF Faculty
04:00 - 14:00
Lectures by this speaker
Thursday, 2024-08-29
Molecular Tumor Board 4: Precision Oncology for Prostate Cancer: Challenging Cases
10:05 - 10:30
![Tira](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/fDyJ3wcHZTKvk8TVFw5fYhiigsQkxYewD77KZmF1.png)
Tira Tan
National Cancer Centre Singapore
Singapore
![Tira](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/fDyJ3wcHZTKvk8TVFw5fYhiigsQkxYewD77KZmF1.png)
Tira Tan
National Cancer Centre Singapore | Singapore
Dr Tira Tan is a Senior Consultant Medical Oncologist at the National Cancer Centre Singapore with a clinical focus in the treatment of breast cancers and early phase drug development. Dr Tan chairs the pre-operative and young women’s breast cancer programs at NCCS and is the divisional deputy director of research as well as a primary and co-investigator on many early and late phase studies specifically in novel therapeutics and treatment strategies in triple negative breast cancer
Sessions by this speaker
Thursday, 2024-08-29
BPOF Faculty
04:00 - 14:00
Lectures by this speaker
Thursday, 2024-08-29
Molecular Tumor Board 5: Integrating IO and ADCs in Triple Negative Breast Cancer
11:30 - 12:00
![Valerie](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/hjEPfLmmMEzq1XRGOlqaP1gMN4eCkXiTyvcFfGg1.png)
Valerie Heong
Tan Tock Seng Hospital
Singapore
![Valerie](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/hjEPfLmmMEzq1XRGOlqaP1gMN4eCkXiTyvcFfGg1.png)
Valerie Heong
Tan Tock Seng Hospital | Singapore
Dr. Valerie Heong is a medical oncologist at Tan Tock Seng Hospital. She received her medical degree from the University of Adelaide, Australia and subsequently trained in medical oncology in Melbourne, Victoria, Australia. She obtained a PhD in molecular biology from the Department of Medical Biology, University of Melbourne, Australia and subsequently moved to Singapore. During her PhD she was awarded the Ovarian Cancer Australia Postgraduate Scholarship and the Bev Gray Ovarian Cancer PhD Scholarship. She is a clinician scientist with a special interest in cancer genetics, breast and gynaecological cancer, drug development and translational research. Her research focuses on development of novel therapeutic agents and biomarker discovery in breast and ovarian cancer.
Sessions by this speaker
Thursday, 2024-08-29
BPOF Faculty
04:00 - 14:00
Lectures by this speaker
Thursday, 2024-08-29
Molecular Tumor Board 3: Precision Oncology for Gynae Malignancies: Immunotherapy, Parpi and Beyond!
08:15 - 08:45
Thursday, 2024-08-29
Molecular Tumor Board 1: Agnostic Markers in Precision Oncology: Challenging Cases
06:00 - 06:30
![Wong](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/61lkwiQw3B0MjkOmwoSip6XqsqDEfdDNvVZ5m1Ta.png)
Wong Nan Soon
OncoCare Cancer Centre
Singapore
![Wong](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/61lkwiQw3B0MjkOmwoSip6XqsqDEfdDNvVZ5m1Ta.png)
Wong Nan Soon
OncoCare Cancer Centre | Singapore
Dr Wong Nan Soon is a Senior Consultant Medical Oncologist at OncoCare Cancer Centre. His subspecialty interests are in the field of breast cancer and gastrointestinal cancers (which include colon cancer, rectal cancer, anal cancer, biliary cancer, pancreatic cancer, liver cancer, GI stromal cancers (GIST), and neuroendocrine cancers. In addition, he is also well versed in the treatment of a wide variety of cancers which include lung cancers, kidney cancers, uterine cancer, cervical cancer, and ovarian cancers. He has more than 20 years of clinical practice.
Sessions by this speaker
Thursday, 2024-08-29
BPOF Faculty
04:00 - 14:00
Lectures by this speaker
Thursday, 2024-08-29
Molecular Tumor Board 5: Integrating IO and ADCs in Triple Negative Breast Cancer
11:30 - 12:00
![Zhang](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/krscQL7BS45PCVeUVEENNdXmpM9h5P65kUElAD4R.png)
Zhang Zewen
National Cancer Centre Singapore
Singapore
![Zhang](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/krscQL7BS45PCVeUVEENNdXmpM9h5P65kUElAD4R.png)
Zhang Zewen
National Cancer Centre Singapore | Singapore
Dr Zhang Zewen is an Associate Consultant in the Department of Medical Oncology, National Cancer Centre Singapore (NCCS), and subspecialized in Breast and Gynecology Cancer. His primary research interest is in Cancer Genetics, and is part of the Cancer Genetics Service team over at NCCS . In addition, he believes in clinical education and mentorship, and holds the appointment of Clinical Instructor with the SingHealth Duke-NUS Oncology Academic Clinical Programme.